Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK2 |
Variant | I559F |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | JAK2 I559F lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). I559F results in the loss of ATP binding and decreased ATP-induced stabilization compared to wild-type Jak2 (PMID: 25825724), and reduced catalytic activity in in vitro assays (PMID: 30092288). |
Associated Drug Resistance | |
Category Variants Paths |
JAK2 mutant JAK2 inact mut JAK2 I559F |
Transcript | NM_004972.4 |
gDNA | chr9:g.5072525A>T |
cDNA | c.1675A>T |
Protein | p.I559F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004972 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322194.1 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322195.1 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_004972.4 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322195 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_004972.3 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322196 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322196.1 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322194 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322194.2 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322195.2 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
NM_001322196.2 | chr9:g.5072525A>T | c.1675A>T | p.I559F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 inact mut | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843). | 27433843 |
JAK2 mutant | childhood B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | JAK2 mutations are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... |
JAK2 mutant | essential thrombocythemia | not applicable | N/A | Guideline | Diagnostic | JAK2 mutations aid in the diagnosis of essential thrombocythemia (NCCN.org). | detail... |
JAK2 mutant | B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | JAK2 mutations are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... |
JAK2 mutant | myelofibrosis | not applicable | N/A | Guideline | Diagnostic | JAK2 mutations aid in the diagnosis of primary myelofibrosis (NCCN.org). | detail... |